Wed, May 14, 8:27 PM (39 days ago)
### Summary of KALA BIO, Inc. (Ticker: KALA) Q1 2025 Financial Performance **Revenue and Profit Margins:** - KALA BIO, Inc. reported no revenue for the quarter ended March 31, 2025, consistent with the previous quarter. - The company incurred a net loss of $8.9 million, an improvement from the $11.8 million loss in the same period last year. **Cash Flow:** - Net cash used in operating activities was $8.8 million, a decrease from $10.8 million in the previous year. - The company had $42.2 million in cash and cash equivalents as of March 31, 2025, down from $51.2 million at the end of 2024. **Earnings Changes:** - The net loss per share attributable to common stockholders was $1.41, an improvement from $4.20 in the same period last year. **Quarterly Performance Discussion:** - The company's financial health remains challenging, with significant operating losses and negative cash flows. - KALA BIO, Inc. continues to rely on external funding, including private placements and grants, to sustain operations. **Trends and Uncertainties:** - The company faces substantial uncertainties, including the need for additional capital, regulatory approvals, and market acceptance of its product candidates. - The success of KPI-012, the company's lead product candidate, is crucial for future financial performance. **Future Operations Impact:** - KALA BIO, Inc. expects to continue incurring significant expenses and operating losses. - The company's ability to generate revenue and achieve profitability is uncertain and depends on successful product development and regulatory approvals.